The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.

Chemotherapy Guideline Kinase inhibitor Non-small cell lung cancer Programed cell death-1 inhibitor Programed death-ligand 1 inhibitor

Journal

International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 22 02 2019
accepted: 06 03 2019
pubmed: 3 5 2019
medline: 8 8 2019
entrez: 4 5 2019
Statut: ppublish

Résumé

According to rapid development of chemotherapy in advanced non-small cell lung cancer (NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually since 2010. In this latest version, all of the procedure was carried out in accordance with grading of recommendations assessment, development and evaluation (GRADE) system. It includes comprehensive literature search, systematic review, and determination of the recommendation by multidisciplinary expert panel which consisted of medical doctors, pharmacists, nurses, statisticians, and patients from patient advocacy group. Recently, we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors. Thus, the guideline proposes to categorize patients into three entities: (1) driver oncogene-positive, (2) PD-L1 ≥ 50%, and (3) others. Based on this subgroup, 31 clinical questions were described. We believe that this attempt enables clinicians to choose appropriate treatment easier. Here, we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC, stages IV.

Identifiants

pubmed: 31049758
doi: 10.1007/s10147-019-01431-z
pii: 10.1007/s10147-019-01431-z
pmc: PMC6545178
doi:

Types de publication

Journal Article Practice Guideline

Langues

eng

Pagination

731-770

Références

J Clin Oncol. 2018 Aug 1;36(22):2244-2250
pubmed: 29864379
Lancet Oncol. 2013 Sep;14(10):981-8
pubmed: 23883922
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Ann Oncol. 2015 Jul;26(7):1401-8
pubmed: 25908605
J Clin Oncol. 2009 Jul 1;27(19):3217-24
pubmed: 19433683
N Engl J Med. 2005 Jul 14;353(2):123-32
pubmed: 16014882
Clin Cancer Res. 2016 Sep 15;22(18):4585-93
pubmed: 27225694
Jpn J Clin Oncol. 2016 May;46(5):462-7
pubmed: 26977054
PLoS One. 2011;6(8):e22681
pubmed: 21829644
J Clin Oncol. 2015 Jul 1;33(19):2197-204
pubmed: 26014294
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
J Clin Oncol. 2007 Nov 20;25(33):5233-9
pubmed: 18024869
Lancet Oncol. 2016 May;17(5):577-89
pubmed: 27083334
N Engl J Med. 2014 Nov 20;371(21):1963-71
pubmed: 25264305
J Clin Oncol. 2005 Oct 1;23(28):6865-72
pubmed: 16192578
N Engl J Med. 2014 Mar 27;370(13):1189-97
pubmed: 24670165
Clin Oncol (R Coll Radiol). 2015 Apr;27(4):187-96
pubmed: 25576353
Lancet Oncol. 2017 Nov;18(11):1454-1466
pubmed: 28958502
Ann Oncol. 2014 Jan;25(1):126-31
pubmed: 24285021
Ann Oncol. 2004 Mar;15(3):419-26
pubmed: 14998843
J Clin Oncol. 2008 Jan 1;26(1):60-5
pubmed: 18165641
J Clin Oncol. 2009 Mar 20;27(9):1405-12
pubmed: 19224857
J Clin Oncol. 2018 May 10;36(14):1405-1411
pubmed: 29596029
J Clin Oncol. 2016 Mar 1;34(7):661-8
pubmed: 26598747
Ann Oncol. 2013 Jan;24(1):54-9
pubmed: 22967997
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
J Clin Oncol. 2013 Aug 10;31(23):2895-902
pubmed: 23835707
J Clin Oncol. 2009 Mar 20;27(9):1394-400
pubmed: 19224850
Lung Cancer. 2016 Dec;102:30-37
pubmed: 27987585
Lancet Oncol. 2015 Dec;16(16):1630-8
pubmed: 26522337
J Cancer Res Clin Oncol. 2016 Jun;142(6):1325-30
pubmed: 26942444
J Clin Oncol. 2016 Aug 20;34(24):2866-73
pubmed: 27432917
J Clin Oncol. 2013 Aug 10;31(23):2849-53
pubmed: 23775961
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
J Clin Oncol. 2018 Mar 20;36(9):841-849
pubmed: 28841389
J Clin Oncol. 2013 Dec 1;31(34):4349-57
pubmed: 24145346
J Clin Oncol. 2005 Nov 20;23(33):8380-8
pubmed: 16293868
J Clin Oncol. 2015 Feb 20;33(6):575-81
pubmed: 25584004
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Thorac Oncol. 2015 Jan;10(1):134-42
pubmed: 25371077
J Clin Oncol. 2004 Jun 1;22(11):2184-91
pubmed: 15169807
J Natl Cancer Inst. 1999 Jan 6;91(1):66-72
pubmed: 9890172
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
Lancet Oncol. 2015 Jul;16(7):830-8
pubmed: 26051236
Lancet Oncol. 2011 Aug;12(8):735-42
pubmed: 21783417
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
J Natl Cancer Inst. 2003 Mar 5;95(5):362-72
pubmed: 12618501
Ann Oncol. 2010 Sep;21(9):1804-1809
pubmed: 20150572
Cochrane Database Syst Rev. 2010 May 12;(5):CD007309
pubmed: 20464750
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
N Engl J Med. 2009 Sep 3;361(10):958-67
pubmed: 19692684
Lancet Oncol. 2010 Feb;11(2):121-8
pubmed: 20022809
Lancet Oncol. 2012 Jan;13(1):e23-31
pubmed: 21764376
J Thorac Oncol. 2012 Sep;7(9):1417-22
pubmed: 22895139
Ann Oncol. 2007 Feb;18(2):317-23
pubmed: 17079694
Lancet Oncol. 2016 Feb;17(2):234-242
pubmed: 26708155
Lancet. 2017 Mar 4;389(10072):917-929
pubmed: 28126333
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Br J Cancer. 2017 Feb 28;116(5):568-574
pubmed: 28103612
Am J Clin Oncol. 2016 Oct;39(5):441-7
pubmed: 25628268
Lancet. 2011 Sep 17;378(9796):1079-88
pubmed: 21831418
J Clin Oncol. 2000 Jun;18(12):2354-62
pubmed: 10856094
J Clin Oncol. 2006 Jun 1;24(16):2549-56
pubmed: 16735708
J Clin Oncol. 2012 Jun 10;30(17):2055-62
pubmed: 22547591
Lancet Oncol. 2014 Feb;15(2):213-22
pubmed: 24439929
J Clin Oncol. 2000 May;18(10):2095-103
pubmed: 10811675
Lancet. 2014 Aug 23;384(9944):665-73
pubmed: 24933332
J Clin Oncol. 2007 Feb 1;25(4):418-23
pubmed: 17264337
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Lancet Oncol. 2017 Dec;18(12):1590-1599
pubmed: 29074098
Oncologist. 2012;17(6):863-70
pubmed: 22581822
J Clin Oncol. 2008 Jul 20;26(21):3543-51
pubmed: 18506025
Br J Cancer. 2000 Aug;83(4):447-53
pubmed: 10945489
JAMA. 2014 May 21;311(19):1998-2006
pubmed: 24846037
Cancer Sci. 2011 May;102(5):1032-7
pubmed: 21272159
Am J Respir Crit Care Med. 2008 Jun 15;177(12):1348-57
pubmed: 18337594
Lancet Oncol. 2014 Oct;15(11):1236-44
pubmed: 25175099
J Thorac Oncol. 2007 Feb;2(2):135-40
pubmed: 17410029
J Thorac Oncol. 2013 Jan;8(1):89-95
pubmed: 23242440
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
J Thorac Oncol. 2011 Nov;6(11):1907-14
pubmed: 22005471
Lancet. 2017 Jul 1;390(10089):29-39
pubmed: 28501140
Lancet Oncol. 2014 Sep;15(10):1119-28
pubmed: 25153538
J Clin Oncol. 2010 Dec 20;28(36):5240-6
pubmed: 21079147
Lancet Oncol. 2010 Jun;11(6):521-9
pubmed: 20493771
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
J Clin Oncol. 2014 Jun 20;32(18):1902-8
pubmed: 24841974
Lancet Oncol. 2016 Jul;17(7):984-993
pubmed: 27283860
Br J Cancer. 2006 Oct 23;95(8):966-73
pubmed: 17047644
Oncologist. 2009 Mar;14(3):253-63
pubmed: 19221167
Lancet. 2009 Oct 24;374(9699):1432-40
pubmed: 19767093
Ann Oncol. 2011 Feb;22(2):376-82
pubmed: 20699278
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Lung Cancer. 2012 Jun;76(3):362-7
pubmed: 22244743
Eur J Cancer. 2015 Sep;51(14):1904-10
pubmed: 26174465
J Thorac Oncol. 2015 Jul;10(7):1058-66
pubmed: 26020125
J Thorac Oncol. 2017 Feb;12(2):403-407
pubmed: 27765535
Clin Cancer Res. 2011 Jun 1;17(11):3812-21
pubmed: 21531810
Lancet Oncol. 2017 Oct;18(10):1307-1316
pubmed: 28919011
Lancet Oncol. 2017 Jul;18(7):874-886
pubmed: 28602779
Lung Cancer. 2016 Sep;99:186-93
pubmed: 27565938
Lancet Oncol. 2015 Feb;16(2):141-51
pubmed: 25589191
Ann Oncol. 2013 Jan;24(1):20-30
pubmed: 23180113
J Thorac Oncol. 2012 Jan;7(1):203-11
pubmed: 22173662
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Lancet Oncol. 2014 Oct;15(11):1254-62
pubmed: 25232001
Lancet Oncol. 2012 Nov;13(11):1161-70
pubmed: 23078958
J Thorac Oncol. 2007 Jun;2(6):494-8
pubmed: 17545843
Ann Oncol. 2017 Nov 01;28(11):2698-2706
pubmed: 29045553
Ann Oncol. 2014 May;25(5):1044-52
pubmed: 24585722
J Thorac Oncol. 2007 Sep;2(9):845-53
pubmed: 17805063
Jpn J Clin Oncol. 2013 Jun;43(6):629-35
pubmed: 23599349
Cancer Chemother Pharmacol. 2001 Nov;48(5):356-60
pubmed: 11761452
J Clin Oncol. 2006 Aug 1;24(22):3657-63
pubmed: 16877734
J Clin Oncol. 2004 May 1;22(9):1589-97
pubmed: 15117980
J Clin Oncol. 2005 Jan 1;23(1):190-6
pubmed: 15625373
Lung Cancer. 2013 Oct;82(1):109-14
pubmed: 23910906
J Thorac Oncol. 2017 Jul;12(7):1161-1166
pubmed: 28238961

Auteurs

Hiroaki Akamatsu (H)

Internal Medicine III, Wakayama Medical University, Wakayama, Japan.

Kiichiro Ninomiya (K)

Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Hirotsugu Kenmotsu (H)

Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.

Masahiro Morise (M)

Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Aichi, Japan.

Haruko Daga (H)

Osaka City General Hospital, Osaka, Japan.

Yasushi Goto (Y)

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

Toshiyuki Kozuki (T)

Clinical Research Center, Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Ehime, Japan.

Satoru Miura (S)

Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.

Takaaki Sasaki (T)

Respiratory Center, Asahikawa Medical University Hospital, Hokkaido, Japan.

Akihiro Tamiya (A)

National Hospital Organization Kinki-chuo Chest Medical Center, Osaka, Japan.

Shunsuke Teraoka (S)

Internal Medicine III, Wakayama Medical University, Wakayama, Japan.

Yukari Tsubata (Y)

Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, Shimane, Japan.

Hiroshige Yoshioka (H)

Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan.

Yoshihiro Hattori (Y)

Department of Thoracic Oncology, Hyogo Cancer Center, Hyogo, Japan.

Chiyo K Imamura (CK)

Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.

Yuki Katsuya (Y)

Department of Surgery, University of California San Diego, California, USA.

Reiko Matsui (R)

National Cancer Center Hospital East, Chiba, Japan.

Yuji Minegishi (Y)

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

Hidenori Mizugaki (H)

First Department of Medicine, Hokkaido University Hospital, Hokkaido, Japan.

Kaname Nosaki (K)

Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.

Yusuke Okuma (Y)

Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan.

Setsuko Sakamoto (S)

Kyushu University Hospital, Fukuoka, Japan.

Takashi Sone (T)

Regional Respiratory Symptomatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.

Kentaro Tanaka (K)

Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Shigeki Umemura (S)

Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.

Takeharu Yamanaka (T)

Department of Biostatistics, Yokohama City University School of Medicine, Kanagawa, Japan.

Shinsuke Amano (S)

Japan Federation of Cancer Patient Groups, Tokyo, Japan.

Kazuo Hasegawa (K)

Japan Lung Cancer Alliance, Tokyo, Japan.

Satoshi Morita (S)

Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Kazuko Nakajima (K)

Shizuoka Cancer Center, Shizuoka, Japan.

Makoto Maemondo (M)

Division of Pulmonary Medicine, Allergry and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate, Japan.

Takashi Seto (T)

Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. setocruise@gmail.com.

Nobuyuki Yamamoto (N)

Internal Medicine III, Wakayama Medical University, Wakayama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH